This filing updates the ELOC terms but does not change the company's fundamental financial distress. The stock is a penny stock with minimal liquidity and a going-concern warning. Any ELOC draws at current prices would be highly dilutive. Monitor for any actual ELOC draws or news on FDA/regulatory progress for nicotine strips, which remain speculative.
Executive Summary
CTT Pharmaceutical Holdings, Inc. filed Amendment No. 2 to its S-1 registration statement, registering 6,250,000 shares for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement. The ELOC provides up to $10 million in potential funding, but the company is a development-stage pharmaceutical firm with no current revenue, a history of losses, and a going-concern qualification from its auditors. The stock trades on the OTCQB at $0.0825 per share, and the filing updates the ELOC terms from the prior S-1 filed in December 2025.
Key Facts
- Registers 6,250,000 shares for resale by RH2 Equity Partners under an ELOC dated September 19, 2025.
- ELOC provides up to $10 million in potential funding, but the company may only receive proceeds if it sells shares to RH2.
- Company is a development-stage pharmaceutical firm with no revenue in the past two years; net loss of $155,907 in FY2025.
- Auditors include a 'going concern' qualification in the financial statements.
- Cash balance as of March 31, 2026 was only $7,089.
- Stock price on May 26, 2026 was $0.0825 per share; at that price, selling all 6.25M registered shares would yield only ~$876,236 in gross proceeds.
- Management states it plans to use no more than $1 million from the ELOC unless the stock price exceeds $1 per share.
- Company has a history of losses and minimal operations; its primary assets are patents expiring between 2028 and 2038.
- Officers and directors collectively own approximately 51.1% of outstanding shares.
Financial Impact
Potential gross proceeds of up to $10 million from ELOC, but at current stock price of $0.0825, selling all 6.25M registered shares would yield only ~$876,236. Company had only $7,089 cash as of March 31, 2026.
Risk Factors
- Going-concern risk: company has minimal cash and no revenue.
- Extreme dilution risk: at current stock price, raising even $1 million would require issuing ~12 million shares (20%+ dilution).
- Regulatory risk: nicotine strips require FDA approval, which is uncertain and costly.
- Penny stock status limits institutional interest and liquidity.
- Management controls ~51% of shares, limiting minority shareholder influence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001171520-26-000117 |
| Exhibit: ex10-2.htm | 0001171520-26-000117 |
| Exhibit: ex10-1.htm | 0001171520-26-000117 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (+0.71%) |
Oct 7, 2026 19d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (−0.71%) |
Aug 12, 2026 10w ago | 8-K | $0.0660 | awaiting T+60 | — | $0.0570 (−13.64%) |
Jul 24, 2026 13w ago | S-1/A | $0.0660 $0.0589 | ▲ +10.76% | ▲ +14.31% | $0.0570 (+13.64%) |
Jun 29, 2026 17w ago | S-1/A | $0.0750 $0.0485 | ▲ +35.33% | ▲ +38.38% | $0.0570 (+24.00%) |
Jun 16, 2026 18w ago | S-1/A | $0.0800 $0.0518 | ▲ +35.25% | ▲ +38.66% | $0.0570 (+28.75%) |
May 29, 2026 21w ago | S-1/A | $0.0720 $0.0570 | ▲ +20.83% | ▲ +22.02% | $0.0570 (+20.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers